4-chloro-2-(2-imidazolin-2-ylamino)isoindoline has been researched along with guanabenz in 1 studies
Studies (4-chloro-2-(2-imidazolin-2-ylamino)isoindoline) | Trials (4-chloro-2-(2-imidazolin-2-ylamino)isoindoline) | Recent Studies (post-2010) (4-chloro-2-(2-imidazolin-2-ylamino)isoindoline) | Studies (guanabenz) | Trials (guanabenz) | Recent Studies (post-2010) (guanabenz) |
---|---|---|---|---|---|
12 | 0 | 1 | 446 | 42 | 96 |
Protein | Taxonomy | 4-chloro-2-(2-imidazolin-2-ylamino)isoindoline (IC50) | guanabenz (IC50) |
---|---|---|---|
trace amine-associated receptor 1 | Homo sapiens (human) | 1.173 | |
Solute carrier family 22 member 1 | Homo sapiens (human) | 4.85 | |
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.204 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.041 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.149 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 1.106 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 2.068 | |
Amine oxidase [flavin-containing] A | Homo sapiens (human) | 1.787 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.472 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.392 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.204 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 2.068 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.097 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Agbaba, D; Filipic, S; Nikolic, K | 1 |
1 other study(ies) available for 4-chloro-2-(2-imidazolin-2-ylamino)isoindoline and guanabenz
Article | Year |
---|---|
QSAR study of imidazoline antihypertensive drugs.
Topics: Antihypertensive Agents; Binding Sites; Imidazoline Receptors; Imidazolines; Ligands; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship | 2008 |